Literature DB >> 29223614

Host susceptibility to MERS-CoV infection, a retrospective cohort study of the 2015 Korean MERS outbreak.

Jae-Hoon Ko1, Hyeri Seok1, Ga Eun Park1, Ji Yeon Lee1, Ji Yong Lee1, Sun Young Cho1, Young Eun Ha1, Ji-Man Kang2, Yae-Jean Kim2, Cheol-In Kang1, Doo Ryeon Chung1, Jae-Hoon Song1, Kyong Ran Peck3.   

Abstract

To evaluate host susceptibility factors to Middle East respiratory syndrome coronavirus (MERS-CoV) infection, we conducted a retrospective cohort study from the single largest exposure event of the 2015 Korean MERS outbreak. A total of 175 patients were closely exposed to a super-spreader, 26 of which were infected (14.9%). In a multivariate analysis, history of autologous stem cell transplantation (HR, 31.151; 95% CI, 5.447-178.145; P < 0.001) and tachypnea at ED (HR, 4.392; 95% CI, 1.402-13.761; P = 0.011) were significantly associated with MERS-CoV infection.
Copyright © 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Middle East respiratory syndrome coronavirus; Stem cell transplantation; Susceptibility; Tachypnea

Mesh:

Year:  2017        PMID: 29223614      PMCID: PMC7129617          DOI: 10.1016/j.jiac.2017.09.008

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


Close exposure is a critical factor for human-to-human transmission of Middle East respiratory syndrome coronavirus (MERS-CoV), but clinical factors affecting host susceptibility to MERS-CoV have not been properly identified [1], [2], [3]. To identify host susceptibility factors to MERS-CoV infection, we performed a retrospective cohort study from the largest exposure event during the 2015 Korean MERS outbreak [3], [4]. A retrospective cohort study was performed to identify risk factors for increased host susceptibility to MERS-CoV. This exposure event was previously described in detail [3]: While a severely-coughing MERS patient stayed at our emergency department (ED) for three days, 675 patients stayed at the ED and had chance to be exposed. After meticulous contact tracing, 175 closely exposed patients were identified and classified into two groups by exposure time and location: group A, patients who stayed in the same examination rooms at the same time with the index case (our ED is composed of zone I ∼ IV for adult patients, and the index case used zone II ∼ IV); and group B, patients who shared the same radiology room or registration area at the same time period (30 min before and 2 h after) with the index case. Exposure sites of group A were subdivided into the zone II, III, and IV, as attack rates of each zone were significantly different (23% (13/57), 32% (7/22), and 8% (3/38), respectively; P = 0.047) [3]. Included patients were followed for 14 days, which is a previously determined incubation period of MERS-CoV [1]. The Institutional Review Board of Samsung Medical Center approved this study. For simple comparison of clinical variables, Student's t-tests or Mann-Whitney U tests were used for continuous variables, and chi-square tests or Fisher's exact tests for categorical variables. The Cox proportional hazard model was used to examine the association of clinical variables with MERS-CoV infection. Variables with statistical significance in univariate analyses were included in the multivariate analysis. The effect of exposure intensity was adjusted by including exposure sites in the multivariate analysis. All P-values were two-tailed, and those <0.05 were considered to be statistically significant. IBM SPSS Statistics version 20.0 for Windows (IBM, Armonk, NY, USA) was used for all statistical analyses. During the study period, a total of 175 patients were closely exposed to the index case, 26 of whom (14.9%) were infected with MERS-CoV (3 patients at radiology rooms or registration area, 13 at zone II, 7 at zone III, and 3 at zone IV) [3]. Baseline characteristics and clinical presentation of the study population at the time of ED visit are presented in Table 1 . There was no statistical difference in age, sex, body mass index, and immunosuppressive conditions. Patients exposed at zone II and III showed higher attack rates as previously described [3]. Among underlying diseases, hypertension and cardiovascular diseases were significantly different between infected and non-infected patients (all P < 0.05). Significantly higher proportion of MERS-infected patients presented with tachypnea (respiratory rate > 24/min) at ED visit, compared to non-infected patients (15.4% (4/26) and 2.7% (4/149), respectively; P = 0.018). The proportion of concomitant infections and laboratory test results were not statistically different between the two groups.
Table 1

Baseline characteristics and clinical presentation of the study population at ED visit.

VariablesInfected with MERS (n = 26)Not infected with MERS (n = 149)P value
Demographics
 Age, years (mean ± SD)56.5 ± 16.852.2 ± 19.90.306
 Male sex13 (50%)61 (40.9%)0.388
 BMI (kg/m2, median, IQR)22.0 (19.8–24.4)22.1 (19.8–24.1)0.992
Exposure sites
 Radiology or registration3 (11.5%)55 (36.9%)0.011
 Zone II13 (50.0%)44 (29.5%)0.040
 Zone III7 (26.9%)15 (10.1%)0.026
 Zone IV3 (11.5%)35 (23.5%)0.173
Immunosuppressive therapies
 Chemotherapy3 (11.5%)36 (24.2%)0.154
 Radiotherapy1 (3.8%)9 (6.0%)1.000
 Steroid use1 (3.8%)2 (1.3%)0.385
Underlying diseases
 Hypertension12 (46.2%)38 (25.5%)0.031
 Diabetes mellitus4 (15.4%)25 (16.8%)1.000
 Cardiovascular diseases9 (34.6%)21 (14.1%)0.020
 Pulmonary diseases1 (3.8%)4 (2.7%)0.557
 Liver diseases1 (3.8%)6 (4.0%)1.000
 Renal diseases2 (7.7%)3 (2.0%)0.160
 Solid cancers9 (34.6%)58 (38.9%)0.676
 Hematologic diseases3 (11.5%)9 (6.0%)0.391
 Autologous SCT2 (7.7%)1 (0.7%)0.058
 Solid organ transplantation0 (0.0%)3 (2.0%)1.000
 Charlson's WIC (median, IQR)2 (1–6)2 (0–6)0.444
Vital signs (median, IQR)
 Fever (>38 °C)6 (23.1%)20 (13.4%)0.231
 Hypotension (MAP < 65)0 (0.0%)7 (4.7%)0.596
 Tachycardia (HR > 90)11 (42.3%)44 (29.5%)0.195
 Tachypnea (RR > 24)4 (15.4%)4 (2.7%)0.018
 SIRS7 (26.9%)36 (24.2%)0.763
Concomitant infections10 (38.5%)45 (32.8%)0.652
 Bacterial8 (30.8%)53 (35.8%)0.795
 Tuberculosis1 (3.8%)1 (0.7%)0.276
 Viral1 (3.8%)7 (4.7%)1.000

Data are expressed as the number (%) of patients, unless indicated otherwise.

Abbreviations: MERS, Middle East respiratory syndrome; SD, standard deviation; BMI, body mass index; IQR, interquartile range; SCT, stem cell transplantation; WIC, weighted index of comorbidity.

Baseline characteristics and clinical presentation of the study population at ED visit. Data are expressed as the number (%) of patients, unless indicated otherwise. Abbreviations: MERS, Middle East respiratory syndrome; SD, standard deviation; BMI, body mass index; IQR, interquartile range; SCT, stem cell transplantation; WIC, weighted index of comorbidity. To identify possible risk factors for increased host susceptibility to MERS-CoV, all the obtained clinical variables and exposure sites were evaluated. History of autologous stem cell transplantation (SCT), underlying hypertension and cardiovascular disease, tachypnea at ED visit, and exposure sties of zone II and III were statistically significantly associated with MERS-CoV infection in univariate analyses (Supplementary Table 1). In the multivariate analysis, history of autologous SCT (HR, 31.151; 95% CI, 5.447–178.145; P < 0.001) and tachypnea at ED visit (HR, 4.392; 95% CI, 1.402–13.761; P = 0.011) were identified as risk factors for increased host susceptibility to MERS-CoV (Table 2 ). Significant association of exposure sties of zone II and III was relevant with the previous analysis [3].
Table 2

Multivariate analysis for host susceptibility factors to MERS-CoV infection.

VariablesUnivariate analysis
Multivariate analysis
HR (95% CI)P valueHR (95% CI)P value
Exposure sites
 Radiology or registration area11
 Zone II4.711 (1.342–16.535)0.0165.990 (1.503–23.867)0.011
 Zone III7.413 (1.916–28.686)0.0045.520 (1.199–25.411)0.028
 Zone IV1.531 (0.309–7.587)0.6021.313 (0.263–6.550)0.740
Autologous SCT6.181 (1.458–26.200)0.01331.151 (5.447–178.145)<0.001
Tachypnea6.535 (2.243–19.037)0.0014.392 (1.402–13.761)0.011
Hypertension2.283 (1.056–4.937)0.0361.872 (0.746–4.698)0.181
Cardiovascular diseases2.788 (1.242–6.257)0.0132.004 (0.762–5.270)0.159

Abbreviations: MERS-CoV, Middle East respiratory syndrome coronavirus; SCT, stem cell transplantation.

Multivariate analysis for host susceptibility factors to MERS-CoV infection. Abbreviations: MERS-CoV, Middle East respiratory syndrome coronavirus; SCT, stem cell transplantation. Although many studies have reported poor prognosis factors of MERS-CoV infection since the discovery of MERS-CoV in 2012, little has been determined about host susceptibility to the virus [1]. Evaluating an exposure cohort for host susceptibility is often not feasible as enough number, medical records, contact tracing, and follow-up of the exposed patients is required. We experienced a unique situation in that discrete population of patients was exposed to the single index case in the defined space of ED, which made it possible to conduct the first cohort study to evaluate host susceptibility to MERS-CoV. Of note, previously reported poor prognostic factors, including old age, male sex, concomitant infection, low albumin concentrations, lymphopenia, diabetes, and multiple comorbidities [3], [5], [6], were not statistically significant in the multivariate analysis. These factors were evaluated in the present cohort with sufficient numbers, and the analysis indicated that they did not play critical roles in host susceptibility to MERS-CoV infection. This finding suggests that risk factors associated with poor prognosis and host susceptibility need to be separately considered. Meticulous surveillance of MERS-CoV exposed patients should be conducted regardless of presence of poor prognosis factors. On the other hand, history of autologous SCT showed statistical significance in the multivariate analysis. Although susceptibility of autologous SCT recipients to viral infections after engraftment has not been well evaluated, two of three autologous SCT recipients (66.7%) in the present cohort were infected with MERS-CoV despite relatively low exposure intensity (at radiology room and zone IV). Because all the autologous SCT recipients in this cohort had underlying lymphoma and had multiple chemotherapy before SCT, whether autologous SCT per se or heavily-treated aggressive lymphoma would be a risk for increased host susceptibility for MERS-CoV infection is not conclusive. Also, immunocompromising conditions generally associated with viral infections including hematologic malignancies other than lymphoma, allogeneic SCT, and corticosteroid use were scarcely included in this cohort [7], [8]. Therefore, it would be more relevant to interpret the present data that severely immunocompromised hosts could be more vulnerable to MERS-CoV infection and need special caution when exposed to the virus. Interestingly, tachypnea at ED (HR, 4.392; 95% CI, 1.402–13.761; P = 0.011) was associated with MERS-CoV infection. Although association between respiratory rate and increased susceptibility to a certain respiratory virus has not been evaluated, theoretically patients with tachypnea may inhale more virus-containing droplets or aerosols. A recent study reported isolation of MERS-CoV from the air in MERS outbreak units, suggesting possibility of air-borne transmission [9]. Although this association needs to be further evaluated, patients with tachypnea at the time of exposure should to be monitored with caution, especially when the exposure occurs from severely-coughing MERS patients at a restricted space. Our study has several limitations. Although we could not identify entire routes of exposed patients, we adjusted the exposure intensity by specific exposure sites. Sizes, structure, crowdedness, exposure time from the index case were different between each site, which resulted in significantly different attack rates by exposure site [3]. In addition, we only evaluated a single exposure cohort, which could be biased by some special situation. In conclusion, in a cohort study from the single largest exposure event, history of autologous SCT and tachypnea at ED were identified as host susceptibility factors to MERS-CoV infection. Previously reported poor prognostic factors did not show association with increased host susceptibility to the virus.

Conflicts of interest

There are no potential conflicts of interest relevant to this article to report.

Funding

This work was supported by the Samsung Biomedical Research Institute (SBRI) grant [#SMX1161321].
  9 in total

1.  Control of an Outbreak of Middle East Respiratory Syndrome in a Tertiary Hospital in Korea.

Authors:  Ga Eun Park; Jae-Hoon Ko; Kyong Ran Peck; Ji Yeon Lee; Ji Yong Lee; Sun Young Cho; Young Eun Ha; Cheol-In Kang; Ji-Man Kang; Yae-Jean Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Jun Haeng Lee; Ik Joon Jo; Byeong-Ho Jeong; Gee Young Suh; Jinkyeong Park; Chi Ryang Chung; Jae-Hoon Song; Doo Ryeon Chung
Journal:  Ann Intern Med       Date:  2016-05-31       Impact factor: 25.391

2.  Clinical presentation and risk factors for cytomegalovirus colitis in immunocompetent adult patients.

Authors:  Jae-Hoon Ko; Kyong Ran Peck; Woo Joo Lee; Ji Yong Lee; Sun Young Cho; Young Eun Ha; Cheol-In Kang; Doo Ryeon Chung; Young-Ho Kim; Nam Yong Lee; Kyoung-Mee Kim; Jae-Hoon Song
Journal:  Clin Infect Dis       Date:  2014-12-01       Impact factor: 9.079

Review 3.  An overview of infectious complications after allogeneic hematopoietic stem cell transplantation.

Authors:  Ugur Sahin; Selami Kocak Toprak; Pinar Ataca Atilla; Erden Atilla; Taner Demirer
Journal:  J Infect Chemother       Date:  2016-06-22       Impact factor: 2.211

4.  An observational, laboratory-based study of outbreaks of middle East respiratory syndrome coronavirus in Jeddah and Riyadh, kingdom of Saudi Arabia, 2014.

Authors:  Christian Drosten; Doreen Muth; Victor M Corman; Raheela Hussain; Malaki Al Masri; Waleed HajOmar; Olfert Landt; Abdullah Assiri; Isabella Eckerle; Ali Al Shangiti; Jaffar A Al-Tawfiq; Ali Albarrak; Alimuddin Zumla; Andrew Rambaut; Ziad A Memish
Journal:  Clin Infect Dis       Date:  2014-10-16       Impact factor: 9.079

Review 5.  Middle East respiratory syndrome.

Authors:  Alimuddin Zumla; David S Hui; Stanley Perlman
Journal:  Lancet       Date:  2015-06-03       Impact factor: 79.321

6.  Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia.

Authors:  Mustafa Saad; Ali S Omrani; Kamran Baig; Abdelkarim Bahloul; Fatehi Elzein; Mohammad Abdul Matin; Mohei A A Selim; Mohammed Al Mutairi; Daifullah Al Nakhli; Amal Y Al Aidaroos; Nisreen Al Sherbeeni; Hesham I Al-Khashan; Ziad A Memish; Ali M Albarrak
Journal:  Int J Infect Dis       Date:  2014-10-07       Impact factor: 3.623

7.  Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study.

Authors:  Abdullah Assiri; Jaffar A Al-Tawfiq; Abdullah A Al-Rabeeah; Fahad A Al-Rabiah; Sami Al-Hajjar; Ali Al-Barrak; Hesham Flemban; Wafa N Al-Nassir; Hanan H Balkhy; Rafat F Al-Hakeem; Hatem Q Makhdoom; Alimuddin I Zumla; Ziad A Memish
Journal:  Lancet Infect Dis       Date:  2013-07-26       Impact factor: 25.071

8.  Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients.

Authors:  Jae-Hoon Ko; Ga Eun Park; Ji Yeon Lee; Ji Yong Lee; Sun Young Cho; Young Eun Ha; Cheol-In Kang; Ji-Man Kang; Yae-Jean Kim; Hee Jae Huh; Chang-Seok Ki; Byeong-Ho Jeong; Jinkyeong Park; Chi Ryang Chung; Doo Ryeon Chung; Jae-Hoon Song; Kyong Ran Peck
Journal:  J Infect       Date:  2016-08-09       Impact factor: 6.072

9.  Extensive Viable Middle East Respiratory Syndrome (MERS) Coronavirus Contamination in Air and Surrounding Environment in MERS Isolation Wards.

Authors:  Sung-Han Kim; So Young Chang; Minki Sung; Ji Hoon Park; Hong Bin Kim; Heeyoung Lee; Jae-Phil Choi; Won Suk Choi; Ji-Young Min
Journal:  Clin Infect Dis       Date:  2016-04-18       Impact factor: 9.079

  9 in total
  3 in total

Review 1.  Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration.

Authors:  Feras M Ghazawi; Megan Lim; Jan P Dutz; Mark G Kirchhof
Journal:  Int J Dermatol       Date:  2020-07-03       Impact factor: 2.736

2.  [COVID-19 and hematopoietic stem cell transplantation: Recommendations].

Authors:  Jihane Toughza; Aomar Agadr; Nabil Ismaili
Journal:  Bull Cancer       Date:  2020-06-20       Impact factor: 1.276

3.  How do we plan hematopoietic cell transplant and cellular therapy with the looming COVID-19 threat?

Authors:  Bhagirathbhai Dholaria; Bipin N Savani
Journal:  Br J Haematol       Date:  2020-03-16       Impact factor: 6.998

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.